Home›Companies›BioDelivera
BioDelivera

Programmable drug delivery precisely targets only diseased cells

BioDelivera has developed proprietary GCV™, a drug delivery platform designed to travel through the body and selectively target diseased cells while sparing healthy ones. GCVs can carry genetic medicines, DNA, RNA, small molecules, or combinations of these at the same time. BioDelivera has demonstrated efficacy in tumors, muscle, and brain and is expanding to additional tissues. The company’s mission is to enable cures for every patient, across every disease.
Active Founders
Ikeda Trashi
Ikeda Trashi
Founder/CEO
Co-founder & CEO of BioDelivera (YC F26), building GCV™ for precise, tissue-specific delivery of next-generation therapeutics. Repeat founder and PhD I am dedicated in enabling cures for every disease.
Orikeda Trashi
Orikeda Trashi
Founder/President
Co-founder & President of BioDelivera (YC F26), building GCV™ for precise, programmable drug delivery to enable cures for every patient, across every disease. During her PhD, she spent five years researching drug delivery systems, developing the foundation for the Guided Chimeric Vehicle (GCV) platform.
Company Launches
BioDelivera - Programmable drug delivery to enable cures for every disease 🎯
See original launch post

TL;DR: Less than 3% of an injected therapy reaches diseased cells. Therapies spread throughout the body, accumulating in healthy organs instead of targeting diseased cells. We’re PhDs and sisters who have built our Guided Chimeric Vehicle (GCV), a programmable platform designed to concentrate therapies in the right cells. We’re unlocking the potential of a multi-$T therapeutics market, long held back by the limits of drug delivery.

Hi everyone, we are twin sisters @Ikeda Trashi (left) and @Orikeda Trashi (right) co-founders of @BioDelivera 🧬

uploaded image

During our everyday lives, we have witnessed small kids, adults, and elderly people having diseases that don’t have a cure because current treatments have limited effectiveness, kill healthy cells, and are not localized.To solve this, we built @BioDelivera on the foundation of five years of PhD research in drug delivery.

❗The Problem❗

When someone gets a drug,most of the drug spreads throughout the body, exposing healthy cells. Poor targeting causes toxicity, making patients sick and forcing lower doses that limit treatment effectiveness. FDA has already identified getting genetic medicines into the right cells inside the body as a major delivery roadblock. Cancer treatments face same challenge, damaging all the healthy organs, making patients very sick.

Current delivery systems are built for specific types of therapies, restricting which medicines we can deliver, which diseases we can treat, and which patients we can reach

🧪 The Solution 🧪

https://www.youtube.com/watch?v=1L7XjQPWti8

We cherry-picked the finest elements and created Guided Chimeric Vehicles (GCVs).

These chimeric nanoparticles are specifically designed to bind to the desired cell. Think of medicine as a package that needs the right delivery vehicle to reach its address instead of being scattered across the city.

Here’s how they work:

● Our GCVs self-assemble around the therapeutic cargo and encapsulate it.

● Once injected intravenously, they bind to the targeted cells.

● They enter those cells and release the therapeutic cargo directly inside.

They are designed to minimize off-target delivery to healthy organs

💉 Inject → 🎯 Target → 🔓 Enter → 📦 Open → 🧬 Deliver

GCVs can deliver everything from small molecules to RNA, DNA, Proteins and Gene Editors, either together or separately.

The platform is programmable to target cells across cancer, brain, muscles, and other hard-to-reach organs, including cells involved in age-related diseases.

This enables the safe delivery of one or multiple therapies at the same time, with repeated dosing if needed.

Decades of research have created powerful therapeutic tools, from RNA to Gene Editors. We’re building GCVs to unlock their potential by delivering them into the cells they need to reach.

Each new payload and target expands what our platform can enable.

Reach out at founders@biodelivera.com

BioDelivera
Founded:2025
Batch:Fall 2026
Team Size:2
Status:
Active
Location:San Francisco
Primary Partner:Nicolas Dessaigne